Joseph G. Pressey · Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care
Follow
Article1 min read·Published Dec 2021Older

Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Dec 2021 · 1 min read

In brief

In brief

This retrospective study examines chemotherapy-induced thrombocytopenia (CIT) in 42 Ewing sarcoma patients, finding that 64% experienced CIT primarily during consolidation therapy with ifosfamide/etoposide. Ten patients received romiplostim with dose-dependent platelet recovery and minimal adverse effects, suggesting potential for maintaining dose-dense treatment intensity.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Background: Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression. Romiplostim is a thrombopoietin receptor agonist that may be useful in the treatment of chemotherapy-induced thrombocytopenia (CIT). Methods: Patients aged between 3 and 33 years with Ewing sarcoma from 2010 to 2020 were reviewed. CIT was defined as a failure to achieve 75,000 platelets per microliter by day 21 after the start of any chemotherapy cycle. Fisher's exact test was used for univariate analysis and Pearson's correlation coefficient was used for the association between continuous variables. Results: Twenty-seven out of 42 patients (64%) developed isolated CIT, delaying one to four chemotherapy cycles per patient. CIT occurred during consolidation therapy in 24/27(88.9%) and with ifosfamide/etoposide cycles in 24/27 (88.9%). Univariate analysis failed to identify risk factors for CIT. The use of radiation approached significance (p-value = .056). Ten patients received romiplostim. The median starting dose was 3 μg/kg (range 1-5). Doses were escalated weekly by 1-2 to 4-10 μg/kg and continued throughout chemotherapy. A higher romiplostim dose was associated with a higher change in average platelet counts from baseline, r = .73 (p = .04). No romiplostim-related adverse events were identified aside from mild headache. Conclusions: CIT is the primary reason for the inability to maintain treatment intensity in Ewing sarc

Statements in this article

  1. Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression.

    EstablishedBackground
  2. Chemotherapy-induced thrombocytopenia was defined as a failure to achieve 75,000 platelets per microliter by day 21 after the start of any chemotherapy cycle.

    GuidelineMethods
  3. Twenty-seven out of 42 patients (64%) developed isolated chemotherapy-induced thrombocytopenia, delaying one to four chemotherapy cycles per patient.

    ResearchResults
  4. Chemotherapy-induced thrombocytopenia occurred during consolidation therapy in 24 of 27 patients (88.9%).

    ResearchResults
  5. Chemotherapy-induced thrombocytopenia occurred with ifosfamide/etoposide cycles in 24 of 27 patients (88.9%).

    ResearchResults
  6. Univariate analysis failed to identify risk factors for chemotherapy-induced thrombocytopenia.

    ResearchResults
  7. The use of radiation approached significance as a risk factor for chemotherapy-induced thrombocytopenia (p-value = .056).

    ResearchResults
  8. The median starting dose of romiplostim was 3 μg/kg (range 1-5).

    ResearchResults
  9. Romiplostim doses were escalated weekly by 1-2 to 4-10 μg/kg and continued throughout chemotherapy.

    ResearchResults
  10. A higher romiplostim dose was associated with a higher change in average platelet counts from baseline, r = .73 (p = .04).

    ResearchResults
  11. No romiplostim-related adverse events were identified aside from mild headache.

    ResearchResults
  12. Chemotherapy-induced thrombocytopenia is the primary reason for the inability to maintain treatment intensity in Ewing sarcoma.

    ResearchConclusions

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.